Recent progress in HER2 associated breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 7, 2015, Pages 2591-2600

  Wang, Wei Jia ^a   Lei, Yuan Yuan ^a   Mei, Jin Hong ^a   Wang, Chun Liang ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Breast cancer; HER2; Mechanism; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOTHERAPY; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MAP KINASE SIGNALING SYSTEM; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84928600474     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.7.2591     Document Type: Review

References (97)

1. Aksamitiene E, Kiyatkin A, Kholodenko BN (2012). Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc T, 40, 139-46.
2. Ali SM, Alpaugh RK, Buell JK, et al (2014). Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer, 14, 14-6.
3. Alqaisi A, Chen L, Romond E, et al (2014). Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat, 148, 437-44.
4. Arcila ME, Chaft JE, Nafa K, et al (2012). Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res, 18.
5. Asp N, Pust S, Sandvig K (2014). Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochim Biophys Acta, 1843, 1987-96.
6. Auvinen P, Rilla K, Tumelius R, et al (2014). Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat, 143, 277-86.
7. Bai WD, Ye XM, Zhang MY, et al (2014). MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer, 135, 1356-68.
8. Ballinger TJ, Sanders ME, Abramson VG (2014). Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy. Clin Breast Cancer.
9. Barroso-Sousa R, Santana IA, Testa L, et al (2013). Biological therapies in breast cancer: common toxicities and management strategies. Breast, 22, 1009-18.
10. Ben-Kasus T, Schechter B, Lavi S, et al (2009). Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA, 106, 3294-9.
11. Bessadottir M, Skuladottir EA, Gowan S, et al (2014). Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells. Phytomedicine, 21, 1717-24.
12. Bilous M, Morey AL, Armes JE, et al (2012). Assessing HER2 amplification in breast cancer: findings from the Australian In situ hybridization program. Breast Cancer Res Treat, 134, 617-24.
13. Blok EJ, Kuppen PJ, van Leeuwen JE, et al (2013). Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clin Med Insights Oncol, 7, 41-51.
14. Boku N (2014). HER2-positive gastric cancer. Gastric Cancer, 17, 1-12.
15. Boulbes DR, Arold ST, Chauhan GB, et al (2014). HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol, 9, 586-600.
16. Brady SW, Zhang J, Seok D, et al (2014). Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor. Mol Cancer Ther, 13, 60-70.
17. Cao J, Jin Y, Li W, et al (2013). DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol, 14, 39.
18. Chen L, Bourguignon LY (2014). Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer, 13, 52.
19. Chmielecki J, Ross JS, Wang K, et al (2014). Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist.
20. Cruz GI, Martinez ME, Natarajan L, et al (2013). Hypothesized role of pregnancy hormones on HER2+ breast tumor development. Breast Cancer Res Treat, 137, 237-46.
21. De Luca A, Maiello MR, D'Alessio A, et al (2012). The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets, 16, 17-27.
22. Delea TE, Hawkes C, Amonkar MM, et al (2013). Cost-effectiveness of lapatinib plus letrozole in post-menopausal women with hormone receptor-and HER2-positive metastatic breast cancer. Breast Care (Basel), 8, 429-37.
23. Dittrich A, Gautrey H, Browell D, et al (2014). The HER2 signaling network in breast cancer-like a spider in its web. J Mammary Gland Biol Neoplasia, [Epub ahead of print].
24. Dong Y, Van Tine BA, Oyama T, et al (2014). Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. Cell Res, 24, 1354-66.
25. Duchnowska R, Jassem J, Goswami CP, et al (2015). Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neurooncol, 122, 205-16.
26. Ebi H, Costa C, Faber AC, et al (2013). PI3K regulates MEK/ERK signaling in breast cancer via the rac-GEF, P-Rex1. Proc Natl Acad Sci U S A, 110, 21124-9.
27. Fountzilas G, Valavanis C, Kotoula V, et al (2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med, 10, 10.
28. Freudenberg JA, Wang Q, Katsumata M, et al (2009). The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol, 87, 1-11.
29. Garrett J, Sutton C, Kuba M, et al (2013). Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res, 19, 610-9.
30. Gennari R, Menard S, Fagnoni F, et al (2004). Pilot study of the mechanism of action ofpreoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res, 10, 5650-5.
31. Gorbatenko A, Olesen CW, Morup N, et al (2014). ErbB2 upregulates the Na+, HCO3 (-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4. Faseb J, 28, 350-63.
32. Green AR, Barros FF, Abdel-Fatah TM, et al (2014). HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat, 145, 33-44.
33. Hosonaga M, Arima Y, Sugihara E, et al (2014). Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. Cancer Sci, 105, 779-87.
34. Huang L, Chen T, Chen C, et al (2013). Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. World J Surg Oncol, 11, 307.
35. Huang W, Wu QD, Zhang M, et al (2015). Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Cancer Lett, 356, 862-71.
36. Huang W, Ye M, Zhang LR, et al (2014). FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation. Mol Cancer, 13, 150.
37. Hudis C, Swanton C, Janjigian YY, et al (2013). A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res, 15, 110.
38. Huynh FC, Jones FE (2014). MicroRNA-7 Inhibits multiple oncogenic pathways to suppress HER2Delta16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS One, 9, 114419.
39. Imami K, Sugiyama N, Imamura H, et al (2012). Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics, 11, 1741-57.
40. Iqbal N, Iqbal N (2014). Human epidermal growth factor receptor 2 (HER2) in Cancers: overexpression and therapeutic implications. Mol Biol Int, 2014, 852748.
41. Kanthala S, Gauthier T, Satyanarayanajois S (2014). Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. Biopolymers, 101, 693-702.
42. Kawajiri H, Takashima T, Kashiwagi S, et al (2015). Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Expert Rev Anticancer Ther, 15, 17-26.
43. Khan S, Shukla S, Sinha S, et al (2015). Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. Int J Biochem Cell Biol, 58, 1-16.
44. Kumler I, Tuxen MK, Nielsen DL (2014). A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev, 40, 259-70.
45. Kurata T, Tsurutani J, Fujisaka Y, et al (2014). Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. Invest New Drugs, 32, 946-54.
46. Ladjemi MZ, Jacot W, Chardes T, et al (2010). Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother, 59, 1295-312.
47. Lanning RM, Morrow M, Riaz N, et al (2015). The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. Ann Surg Oncol.
48. Lapin V, Shirdel EA, Wei X, et al (2014). Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy. Oncogenesis, 3, 133.
49. Lee HJ, Seo AN, Kim EJ, et al (2015). Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer, 112, 103-11.
50. Lee MY, Marina M, King JL, et al (2014). Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells. Cell Div, 9, 3.
51. Leivonen SK, Sahlberg KK, Makela R, et al (2014). High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol, 8, 93-104.
52. Li JW, Mo M, Yu KD, et al (2014). ER-Poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. PLoS One, 9, 114646.
53. Liu Y, Liu Q, Wang T, et al (2013). Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer, 13, 202.
54. Luo TY, Cheng PC, Chiang PF, et al (2015). (188) Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Ann Nucl Med, 29, 52-62.
55. Luu T, Chung C, Somlo G (2011). Combining emerging agents in advanced breast cancer. Oncologist, 16, 760-71.
56. Mehta A, Tripathy D (2014). Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast, 23, 2-9.
57. Menendez JA, Vazquez-Martin A, Garcia-Villalba R, et al (2008). tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). BMC Cancer, 8, 377.
58. Mirmalek SA, Hajilou M, Salimi Tabatabaee SA, et al (2014). Prevalence of HER-2 and hormone receptors and P53 mutations in the pathologic specimens of breast cancer patients. Int J Breast Cancer, 2014, 564308.
59. Mittendorf EA, Liu Y, Tucker SL, et al (2010). A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene, 29, 3896-907.
60. Mohd Sharial MSN, Crown J, Hennessy BT (2012). Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol, 23, 3007-16.
61. Moody SE, Schinzel AC, Singh S, et al (2014). PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene, [Epub ahead of print].
62. Morrison G, Fu X, Shea M, et al (2014). Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat, 144, 263-72.
63. Mortimer JE, Bading JR, Colcher DM, et al (2014). Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med, 55, 23-9.
64. Muendlein A, Hubalek M, Geller-Rhomberg S, et al (2014). Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. Eur J Cancer, 50, 2134-41.
65. Nahta R (2012). Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol, 2012.
66. Nair R, Roden DL, Teo WS, et al (2014). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, 33, 3992-4002.
67. Nam S, Chang HR, Jung HR, et al (2015). A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. Cancer Lett, 356, 880-90.
68. Nielsen BS, Balslev E, Poulsen TS, et al (2014). miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front Oncol, 4, 207.
69. Omenn GS, Guan Y, Menon R (2014). A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines. J Proteomics, 107, 103-12.
70. Pandey JP, Kistner-Griffin E, Black L, et al (2014). IGKC and FcgammaR genotypes and humoral immunity to HER2 in breast cancer. Immunobiol, 219, 113-7.
71. Pang B, Sun SP, Gao L, et al (2014). A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer. Med Oncol, 31, 30.
72. Pazhoomand R, Keyhani E, Banan M, et al (2013). Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR. Asian Pac J Cancer Prev, 14, 7621-8.
73. Prat A, Carey LA, Adamo B, et al (2014). Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst, 106.
74. Rakha EA, Pinder SE, Bartlett JM, et al (2015). Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol, 68, 93-9
75. Rimawi MF, Aleixo SB, Rozas AA, et al (2014). A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer.
76. Rouanet P, Roger P, Rousseau E, et al (2014). HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med, 3, 134-42.
77. Rugo HS, Brufsky AM, Ulcickas Yood M, et al (2013). Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat, 141, 461-70.
78. Scaltriti M, Nuciforo P, Bradbury I, et al (2014). High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res, 21, 569-76.
79. Schroeder RL, Stevens CL, Sridhar J (2014). Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules, 19, 15196-212.
80. Sclafani F, Roy A, Cunningham D, et al (2013). HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol, 24, 3123-8.
81. Segovia-Mendoza M, Diaz L, Gonzalez-Gonzalez ME, et al (2015). Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells. J Steroid Biochem Mol Biol, 148, 122-31
82. Shinde AM, Zhai J, Yu KW, et al (2015). Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab. Breast, 24, 18-23.
83. Spicer J, Baird R, Suder A, et al (2015). Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. Eur J Cancer, 51, 137-45.
84. Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, et al (2014). An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS One, 9, 116054.
85. Tagliabue E, Campiglio M (2014). "Omics" and Immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. Front Oncol, 4, 334.
86. Takada M, Higuchi T, Tozuka K, et al (2013). Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer, 13, 241.
87. Tolaney SM, Barry WT, Dang CT, et al (2015). Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med, 372, 134-41.
88. Victorino VJ, Campos FC, Herrera AC, et al (2014). Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. Tumour Biol, 35, 3025-34.
89. Wu Y, Mohamed H, Chillar R, et al (2008). Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res, 10, 3.
90. Xia W, Petricoin EF, Zhao S, et al (2013). An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res, 15, 85.
91. Xu C, Chen H, Wang X, et al (2014). S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. J Biol Chem, 289, 827-37.
92. Yan Y, Hein AL, Greer PM, et al (2014). A novel function of HER2/Neu in the activation of G2/M checkpoint in response to gamma-irradiation. Oncogene, 0. [Epub ahead of print]
93. Yeh ES, Abt MA, Hill EG (2014). Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. Breast Cancer Res Treat, 149, 91-8
94. Yu AF, Yadav NU, Lung BY, et al (2015). Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat, 149, 489-95.
95. Zang F, Wei X, Leng X, et al (2014). C-FLIP (L) contributes to TRAIL resistance in HER2-positive breast cancer. Biochem Biophys Res Commun, 450, 267-73.
96. Zhang S, Huang WC, Li P, et al (2011). Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med, 17, 461-9.
97. Zhu ZL, Zhang J, Chen ML, et al (2013). Efficacy and safety of trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Asian Pac J Cancer Prev, 14, 7111-6.